Treatment of chronic myeloid leukemia in the imatinib era
BACKGROUND There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives inclu...
Gespeichert in:
| Veröffentlicht in: | Cancer 2007-03, Vol.109 (6), p.1138-1145 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1145 |
|---|---|
| container_issue | 6 |
| container_start_page | 1138 |
| container_title | Cancer |
| container_volume | 109 |
| creator | Aziz, Zeba Iqbal, J Akram, M Saeed, S |
| description | BACKGROUND There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival. METHODS Two hundred seventy-five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR-ABL positive in peripheral blood by polymerase chain reaction. RESULTS After a median follow-up of 18 months, major cytogenetic responses (Ph |
| doi_str_mv | 10.1002/cncr.22507 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_17696586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17696586</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_176965863</originalsourceid><addsrcrecordid>eNqNyjkOwjAQQFEXIBGWhhNMRZfgOGSrEYgDUNBFxkyUAS9gOwW3h4IDUH096TO2znmWcy62yiqfCVHyesISznmTlrviMmPzEO5f1qIsEtaePcpo0EZwPajBO0sKzBu1oxtoHB9oSAJZiAMCGRnJ0hXQyyWb9lIHXP26YJvj4bw_pU_vXiOG2BkKCrWWFt0Yuryu2qpsquLv8QP48z2o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17696586</pqid></control><display><type>article</type><title>Treatment of chronic myeloid leukemia in the imatinib era</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Aziz, Zeba ; Iqbal, J ; Akram, M ; Saeed, S</creator><creatorcontrib>Aziz, Zeba ; Iqbal, J ; Akram, M ; Saeed, S</creatorcontrib><description>BACKGROUND There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival. METHODS Two hundred seventy-five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR-ABL positive in peripheral blood by polymerase chain reaction. RESULTS After a median follow-up of 18 months, major cytogenetic responses (Ph <35%) in chronic phase (CP), accelerated phase (AP), and blastic phase (BP) were documented in 61%, 57%, and 28% of patients, respectively. A complete cytogenetic response was observed in 39.4%, 35.7%, and 14.3% of patients in CP, AP, and BP, respectively; and a complete hematologic response was observed in 90%, 86%, and 30%, respectively. The median time to progression at 18 months was 91% in CP and 68% in AP. The overall survivals in CP, AP, and BP at 18 months was 92%, 74%, and 38%, respectively. CONCLUSIONS Impressive hematologic, cytogenetic, and molecular responses to imatinib were observed, similar to the responses reported in patients from Western countries. Patients had good compliance, toxicity was limited, and overall quality of life was improved markedly. The results indicated that the biology of CML is not different in patients from developing countries. Cancer 2007.</description><identifier>ISSN: 0008-543X</identifier><identifier>DOI: 10.1002/cncr.22507</identifier><language>eng</language><ispartof>Cancer, 2007-03, Vol.109 (6), p.1138-1145</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Aziz, Zeba</creatorcontrib><creatorcontrib>Iqbal, J</creatorcontrib><creatorcontrib>Akram, M</creatorcontrib><creatorcontrib>Saeed, S</creatorcontrib><title>Treatment of chronic myeloid leukemia in the imatinib era</title><title>Cancer</title><description>BACKGROUND There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival. METHODS Two hundred seventy-five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR-ABL positive in peripheral blood by polymerase chain reaction. RESULTS After a median follow-up of 18 months, major cytogenetic responses (Ph <35%) in chronic phase (CP), accelerated phase (AP), and blastic phase (BP) were documented in 61%, 57%, and 28% of patients, respectively. A complete cytogenetic response was observed in 39.4%, 35.7%, and 14.3% of patients in CP, AP, and BP, respectively; and a complete hematologic response was observed in 90%, 86%, and 30%, respectively. The median time to progression at 18 months was 91% in CP and 68% in AP. The overall survivals in CP, AP, and BP at 18 months was 92%, 74%, and 38%, respectively. CONCLUSIONS Impressive hematologic, cytogenetic, and molecular responses to imatinib were observed, similar to the responses reported in patients from Western countries. Patients had good compliance, toxicity was limited, and overall quality of life was improved markedly. The results indicated that the biology of CML is not different in patients from developing countries. Cancer 2007.</description><issn>0008-543X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqNyjkOwjAQQFEXIBGWhhNMRZfgOGSrEYgDUNBFxkyUAS9gOwW3h4IDUH096TO2znmWcy62yiqfCVHyesISznmTlrviMmPzEO5f1qIsEtaePcpo0EZwPajBO0sKzBu1oxtoHB9oSAJZiAMCGRnJ0hXQyyWb9lIHXP26YJvj4bw_pU_vXiOG2BkKCrWWFt0Yuryu2qpsquLv8QP48z2o</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>Aziz, Zeba</creator><creator>Iqbal, J</creator><creator>Akram, M</creator><creator>Saeed, S</creator><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20070301</creationdate><title>Treatment of chronic myeloid leukemia in the imatinib era</title><author>Aziz, Zeba ; Iqbal, J ; Akram, M ; Saeed, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_176965863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aziz, Zeba</creatorcontrib><creatorcontrib>Iqbal, J</creatorcontrib><creatorcontrib>Akram, M</creatorcontrib><creatorcontrib>Saeed, S</creatorcontrib><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aziz, Zeba</au><au>Iqbal, J</au><au>Akram, M</au><au>Saeed, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of chronic myeloid leukemia in the imatinib era</atitle><jtitle>Cancer</jtitle><date>2007-03-01</date><risdate>2007</risdate><volume>109</volume><issue>6</issue><spage>1138</spage><epage>1145</epage><pages>1138-1145</pages><issn>0008-543X</issn><abstract>BACKGROUND There is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival. METHODS Two hundred seventy-five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR-ABL positive in peripheral blood by polymerase chain reaction. RESULTS After a median follow-up of 18 months, major cytogenetic responses (Ph <35%) in chronic phase (CP), accelerated phase (AP), and blastic phase (BP) were documented in 61%, 57%, and 28% of patients, respectively. A complete cytogenetic response was observed in 39.4%, 35.7%, and 14.3% of patients in CP, AP, and BP, respectively; and a complete hematologic response was observed in 90%, 86%, and 30%, respectively. The median time to progression at 18 months was 91% in CP and 68% in AP. The overall survivals in CP, AP, and BP at 18 months was 92%, 74%, and 38%, respectively. CONCLUSIONS Impressive hematologic, cytogenetic, and molecular responses to imatinib were observed, similar to the responses reported in patients from Western countries. Patients had good compliance, toxicity was limited, and overall quality of life was improved markedly. The results indicated that the biology of CML is not different in patients from developing countries. Cancer 2007.</abstract><doi>10.1002/cncr.22507</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2007-03, Vol.109 (6), p.1138-1145 |
| issn | 0008-543X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17696586 |
| source | Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Treatment of chronic myeloid leukemia in the imatinib era |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A07%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20chronic%20myeloid%20leukemia%20in%20the%20imatinib%20era&rft.jtitle=Cancer&rft.au=Aziz,%20Zeba&rft.date=2007-03-01&rft.volume=109&rft.issue=6&rft.spage=1138&rft.epage=1145&rft.pages=1138-1145&rft.issn=0008-543X&rft_id=info:doi/10.1002/cncr.22507&rft_dat=%3Cproquest%3E17696586%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17696586&rft_id=info:pmid/&rfr_iscdi=true |